Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (8)
  • Open Access


    A Construction of Object Detection Model for Acute Myeloid Leukemia

    K. Venkatesh1,*, S. Pasupathy1, S. P. Raja2

    Intelligent Automation & Soft Computing, Vol.36, No.1, pp. 543-560, 2023, DOI:10.32604/iasc.2023.030701

    Abstract The evolution of bone marrow morphology is necessary in Acute Myeloid Leukemia (AML) prediction. It takes an enormous number of times to analyze with the standardization and inter-observer variability. Here, we proposed a novel AML detection model using a Deep Convolutional Neural Network (D-CNN). The proposed Faster R-CNN (Faster Region-Based CNN) models are trained with Morphological Dataset. The proposed Faster R-CNN model is trained using the augmented dataset. For overcoming the Imbalanced Data problem, data augmentation techniques are imposed. The Faster R-CNN performance was compared with existing transfer learning techniques. The results show that the Faster R-CNN performance was significant… More >

  • Open Access


    MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide

    Zhiguo Wang*†1, Zehui Fang‡1, Runzhang Lu, Hongli Zhao, Tiejun Gong, Dong Liu, Luojia Hong, Jun Ma, Mei Zhang*

    Oncology Research, Vol.27, No.9, pp. 1035-1042, 2019, DOI:10.3727/096504019X15528367532612

    Abstract Although arsenic trioxide (ATO) is a well-known antileukemic drug used for acute promyelocytic leukemia treatment, the development of ATO resistance is still a big challenge. We previously reported that microRNA- 204 (miR-204) was involved in the regulation of acute myeloid leukemia (AML) cell apoptosis, but its role in chemoresistance is poorly understood. In the present study, we showed that miR-204 was significantly increased in AML cells after ATO treatment. Interestingly, the increased miR-204 level that was negatively correlated with ATO induced the decrease in cell viability and baculoviral inhibition of apoptosis protein repeatcontaining 6 (BIRC6) expression. Overexpression of miR-204 potentiated… More >

  • Open Access


    RAS-Responsive Element-Binding Protein 1 Blocks the Granulocytic Differentiation of Myeloid Leukemia Cells

    Juanjuan Yao*, Liang Zhong, Pengqiang Zhong*, Dongdong Liu, Zhen Yuan, Junmei Liu*, Shifei Yao*, Yi Zhao*, Min Chen*, Lianwen Li*, Lu Liu, Beizhong Liu*†

    Oncology Research, Vol.27, No.7, pp. 809-818, 2019, DOI:10.3727/096504018X15451301487729

    Abstract RAS-responsive element-binding protein 1 (RREB1) is a transcription factor that is implicated in RAS signaling and multiple tumors. However, the role of RREB1 in acute myeloid leukemia has not been studied. We found that RREB1 is overexpressed in AML patients and myeloid leukemia cell lines (NB4 and HL-60), and RREB1 expression was significantly decreased during granulocytic differentiation of myeloid leukemia cells induced by all-trans retinoic acid (ATRA). Then we performed a RREB1 knockdown assay in NB4 and HL-60 cells; the results showed that knockdown of RREB1 upregulated expression of CD11b, CEBP , and microRNA-145 (miR-145), which hinted that knockdown of… More >

  • Open Access


    Knockdown of IARS2 Inhibited Proliferation of Acute Myeloid Leukemia Cells by Regulating p53/p21/PCNA/eIF4E Pathway

    Hong Li*1, Yaning Tian*1, Xiang Li*, Bin Wang, Dongzhi Zhai*, Yingying Bai*, Changhu Dong*, Xu Chao*‡

    Oncology Research, Vol.27, No.6, pp. 673-680, 2019, DOI:10.3727/096504018X15426261956343

    Abstract IARS2 encodes mitochondrial isoleucine-tRNA synthetase, which mutation may cause multiple diseases. However, the biological function of IARS2 on acute myeloid leukemia (AML) has not yet been identified. In the present study, qRT-PCR was used to determine the expression of IARS2 in K562, THP1, and HL-60 leukemia cells. Additionally the mRNA levels of IARS2 in CD34 cells and AML cells obtained from patients were detected by qRT-PCR. IARS2-shRNA lentiviral vector was established and used to infect acute myeloid leukemia HL-60 cells. qRT-PCR and Western blot analysis were employed to assess the knockdown effect of IARS2. The proliferation rate and cell cycle… More >

  • Open Access


    miRNA–mRNA Profiling Reveals Prognostic Impact of SMC1A Expression in Acute Myeloid Leukemia

    Nikhil Gadewal*1, Rohit Kumar†1, Swapnil Aher, Anagha Gardane, Tarang Gaur, Ashok K. Varma*‡§, Navin Khattry, Syed K. Hasan†§¶

    Oncology Research, Vol.28, No.3, pp. 321-330, 2020, DOI:10.3727/096504020X15816752427321

    Abstract Acute myeloid leukemia (AML) with NPM1 mutation is a disease driving genetic alteration with good prognosis. Although it has been suggested that NPM1 mutation induces chemosensitivity in leukemic cells, the underlying cause for the better survival of NPM1 mutated patients is still not clear. Mutant NPM1 AML has a unique microRNA and their target gene (mRNA) signature compared to wild-type NPM1. Dynamic regulation of miRNA–mRNA has been reported to influence the prognostic outcome. In the present study, in silico expression data of miRNA and mRNA in AML patients was retrieved from genome data commons, and differentially expressed miRNA and mRNA… More >

  • Open Access


    miR-4792 Inhibits Acute Myeloid Leukemia Cell Proliferation and Invasion and Promotes Cell Apoptosis by Targeting Kindlin-3

    Yun Qin*, Yu Wang†‡§, Dongbo Liu

    Oncology Research, Vol.28, No.4, pp. 357-369, 2020, DOI:10.3727/096504020X15844389264424

    Abstract It has been reported that kindlin-3 expression is closely associated with progression of many cancers and microRNA (miRNA) processing. However, the effects and precise mechanisms of kindlin-3 in acute myeloid leukemia (AML) have not been well clarified. Our study aimed to explore the interaction between kindlin-3 and miR-4792 in AML. In our study, we found that the expression of kindlin-3 was dramatically increased in AML samples and cell lines, and the miR-4792 level was significantly downregulated. Interestingly, the low miR-4792 level was closely associated with upregulated kindlin-3 expression in AML samples. Moreover, introduction of miR-4792 dramatically suppressed proliferation and invasion… More >

  • Open Access


    A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells

    Hossam Kamli*, Gaffar S. Zaman*, Ahmad Shaikh*, Abdullah A. Mobarki, Prasanna Rajagopalan*‡

    Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558

    Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by 1 H NMR, 13C NMR, and mass spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1 cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was… More >

  • Open Access


    Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

    Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

    Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

    Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

Displaying 1-10 on page 1 of 8. Per Page  

Share Link